The parts you don't see, documented.
Hormone care is serious medicine. This page explains who reviews your case, who runs your labs, where your medication comes from, and how we handle evidence.
The provider network
Consultations and prescriptions on Xilo come from independent, licensed healthcare providers credentialed in the state where you live. Providers are physicians, nurse practitioners, and physician associates with prescriptive authority, operating under their own clinical judgment. Xilo is the platform; the medical decisions are theirs, and no Xilo revenue target ever changes a clinical decision.
Lab partners
All Xilo panels are processed by CLIA-accredited laboratory partners. At-home collection is a screening method: for borderline results, providers may require confirmatory venous testing before treatment, consistent with clinical guidelines for diagnosing low testosterone.
Pharmacy standards
Prescriptions are filled by state-licensed US pharmacies. Where compounded formulations are used, they are prepared by licensed compounding pharmacies; compounded drugs are not FDA-approved, and we say so everywhere the product appears.
Monitoring policy
Every Rx plan includes follow-up testing, because prescribing without verifying is not treatment, it is retail. Week-8 panels check response; longer plans add periodic monitoring. Providers adjust or discontinue treatment when the data says to.
How we talk about research.
Three rules govern every claim on this site.
Studies are cited, not borrowed
When we reference research, we describe what was studied and in whom. Study populations are not a promise about you.
Mechanisms are not outcomes
"Supports natural production" describes how a therapy works. Whether it works for you is what your follow-up labs are for.
The honest no
If your labs do not support treatment, the provider recommendation is no, and the site is built so that answer is always acceptable.
Citations used across this site.
Numbered references correspond to the superscript markers on product and category pages.
- [1] Fertility preservation with production-stimulating therapy. Peer-reviewed studies of enclomiphene-class oral therapy reported maintained sperm parameters in treated cohorts, in contrast to exogenous testosterone replacement. Final citation list pending medical review before production launch.
- [2] Prevalence of low testosterone. Published epidemiological research estimates a substantial minority of men over 30 have below-reference or symptomatic low testosterone. Final citation list pending medical review before production launch.
- [3] Onset of level changes. Short-term clinical research on oral production-stimulating therapy reported measurable increases in total testosterone within two to four weeks in treated men. Final citation list pending medical review before production launch.
Scrutiny is a feature.
If something here is unclear, ask the care team. If a claim looks stronger than its evidence, tell us; we would rather fix it than defend it.